Article Cited by others

INVITED REVIEW

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance

Edlind Merritt P, Hsieh Andrew C

Year : 2014| Volume: 16| Issue : 3 | Page no: 378-386

   This article has been cited by
 
1 Hierarchical Micro-Nano Topography Promotes Cell Adhesion and Osteogenic Differentiation via Integrin a2-PI3K-AKT Signaling Axis
Huimin Zheng,Yujuan Tian,Qian Gao,Yingjie Yu,Xianyou Xia,Zhipeng Feng,Feng Dong,Xudong Wu,Lei Sui
Frontiers in Bioengineering and Biotechnology. 2020; 8
[Pubmed]  [Google Scholar] [DOI]
2 Fusion transcript detection using spatial transcriptomics
Stefanie Friedrich,Erik L. L. Sonnhammer
BMC Medical Genomics. 2020; 13(1)
[Pubmed]  [Google Scholar] [DOI]
3 RNA-binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression
Jing Zhao,Yu Zhang,Xi-sheng Liu,Fang-ming Zhu,Feng Xie,Chen-yi Jiang,Zi-ye Zhang,Ying-li Gao,Yong-chuan Wang,Bin Li,Shu-jie Xia,Bang-min Han
Cancer Science. 2020;
[Pubmed]  [Google Scholar] [DOI]
4 Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation
He Wenjing,Yuanyuan Shao,Yi Yu,Wei Huang,Guoliang Feng,Junhe Li
The Prostate. 2020;
[Pubmed]  [Google Scholar] [DOI]
5 CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel
Marjan Aghajani,Ahad Mokhtarzadeh,Leili Aghebati-Maleki,Behzad Mansoori,Ali Mohammadi,Sahar Safaei,Zahra Asadzadeh,Khalil Hajiasgharzadeh,Vahid Khaze Shahgoli,Behzad Baradaran
Molecular Biology Reports. 2020;
[Pubmed]  [Google Scholar] [DOI]
6 Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
Miriam Kokal,Kimia Mirzakhani,Thanakorn Pungsrinont,Aria Baniahmad
Cancers. 2020; 12(7): 1833
[Pubmed]  [Google Scholar] [DOI]
7 Novel Nanococktail of a Dual PI3K/mTOR Inhibitor and Cabazitaxel for Castration-Resistant Prostate Cancer
Yee Huang,Xiangdong Xue,Xiaocen Li,Bei Jia,Chong-Xian Pan,Yuanpei Li,Tzu-Yin Lin
Advanced Therapeutics. 2020; : 2000075
[Pubmed]  [Google Scholar] [DOI]
8 Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
Sabina Luszczak,Benjamin S. Simpson,Urszula Stopka-Farooqui,Vignesh Krishna Sathyadevan,Lina M. Carmona Echeverria,Christopher Kumar,Helena Costa,Aiman Haider,Alex Freeman,Charles Jameson,Marzena Ratynska,Imen Ben-Salha,Ashwin Sridhar,Greg Shaw,John D. Kelly,Hayley Pye,Kathy A. Gately,Hayley C. Whitaker,Susan Heavey
Scientific Reports. 2020; 10(1)
[Pubmed]  [Google Scholar] [DOI]
9 Increased ABCC4 Expression Induced by ERRa Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer
Houbao Huang,Jing Li,Jing Shen,Ling Lin,Xu Wu,Shixin Xiang,Yawei Li,Yujie Xu,Qijie Zhao,Yueshui Zhao,Parham Jabbarzadeh Kaboli,Mingxing Li,Xiang Li,Weiping Wang,Qinglian Wen,Zhangang Xiao
Frontiers in Oncology. 2020; 10
[Pubmed]  [Google Scholar] [DOI]
10 The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Boris Y. Shorning,Manisha S. Dass,Matthew J. Smalley,Helen B. Pearson
International Journal of Molecular Sciences. 2020; 21(12): 4507
[Pubmed]  [Google Scholar] [DOI]
11 Fetuin B overexpression suppresses proliferation, migration, and invasion in prostate cancer by inhibiting the PI3K/AKT signaling pathway
Kai Zhan,Rui Liu,Hang Tong,Shun Gao,Guang Yang,Arman Hossain,Tinghao Li,Weiyang He
Biomedicine & Pharmacotherapy. 2020; 131: 110689
[Pubmed]  [Google Scholar] [DOI]
12 Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets
Fabrizio Fontana,Michela Raimondi,Monica Marzagalli,Alessandro Di Domizio,Patrizia Limonta
Cells. 2020; 9(2): 460
[Pubmed]  [Google Scholar] [DOI]
13 Cellular growth factors as prospective therapeutic targets for combination therapy in androgen independent prostate cancer (AIPC)
Bhavana Jonnalagadda,Sumathy Arockiasamy,Sriram Krishnamoorthy
Life Sciences. 2020; : 118208
[Pubmed]  [Google Scholar] [DOI]
14 Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway
Fangzhen Cai,Yanmei Zhang,Jianwei Li,Sihuai Huang,Ruilin Gao
Bioscience Reports. 2020; 40(3)
[Pubmed]  [Google Scholar] [DOI]
15 SNX-2112, an Hsp90 inhibitor, suppresses cervical cancer cells proliferation, migration, and invasion by inhibiting the Akt/mTOR signaling pathway
Liang-Shun Fu,Hong-Hong Qiu,Min Liu,Liu-Bing Hu,Yan Wang,Peng-Chao Zhang,Man-Mei Li,Yi-Fei Wang,Zhong Liu
Medicinal Chemistry Research. 2020;
[Pubmed]  [Google Scholar] [DOI]
16

Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway

Bin Wang,Jingyu Li
Cancer Management and Research. 2020; Volume 12: 2631
[Pubmed]  [Google Scholar] [DOI]
17 Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer
Teng Ma,Hua Chen,Peilong Wang,Ningqiang Yang,Junsheng Bao
Cancer Biotherapy and Radiopharmaceuticals. 2020;
[Pubmed]  [Google Scholar] [DOI]
18 pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks
Ege Ulgen,Ozan Ozisik,Osman Ugur Sezerman
Frontiers in Genetics. 2019; 10
[Pubmed]  [Google Scholar] [DOI]
19 CircLMTK2 acts as a tumor suppressor in prostate cancer via regulating the expression of microRNA-183
Chengjun Jin,Weiming Zhao,Zijian Zhang,Wanpeng Liu
Life Sciences. 2019; : 117097
[Pubmed]  [Google Scholar] [DOI]
20 ABT-737 and erufosine combination against castration-resistant prostate cancer
Ezgi Avsar Abdik,Ferda Kaleagasioglu,Hüseyin Abdik,Fikrettin Sahin,Martin R. Berger
Anti-Cancer Drugs. 2019; 30(4): 383
[Pubmed]  [Google Scholar] [DOI]
21 Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer
Giorgio Ivan Russo,Jörg Hennenlotter,Ulrich Vogel,Ursula Kühs,Thomas Manfred Wurm,Valentina Gerber,Tim Neumann,Sebastiano Cimino,Arnulf Stenzl,Tilman Todenhöfer
Disease Markers. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
22 MIIP inhibits the growth of prostate cancer via interaction with PP1a and negative modulation of AKT signaling
Guang Yan,Yi Ru,Fengqi Yan,Xin Xiong,Wei Hu,Tao Pan,Jianming Sun,Chi Zhang,Qinghao Wang,Xia Li
Cell Communication and Signaling. 2019; 17(1)
[Pubmed]  [Google Scholar] [DOI]
23 Cross-talk between ribosome biogenesis, translation, and mTOR in CD133+?4/CD44+?prostate cancer stem cells
Z. Binal,E. Açikgöz,F. Kizilay,G. Öktem,B. Altay
Clinical and Translational Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]
24 Effect of Sulfated Polysaccharide from Undaria pinnatifida (SPUP) on Proliferation, Migration, and Apoptosis of Human Prostatic Cancer
Xiaolin Xu,Xin Zhu,Wenglong Lu,Yandong He,Yihan Wang,Feng Liu
International Journal of Polymer Science. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
25 Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway
Yuxi Tian,Liangfang Shen,Fujun Li,Junwen Yang,Xiaoping Wan,Miao Ouyang
Journal of Cellular Physiology. 2019;
[Pubmed]  [Google Scholar] [DOI]
26 ING5 inhibits cancer aggressiveness by inhibiting Akt and activating p53 in prostate cancer
Neslisah Barlak,Ozel Capik,Fatma Sanli,Ahsen Kilic,Abdulmelik Aytatli,Aysenur Yazici,Serkan Ortucu,Michael Ittmann,Omer Faruk Karatas
Cell Biology International. 2019;
[Pubmed]  [Google Scholar] [DOI]
27 DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals
Xiaoyu Chen,Xiufang Xiong,Danrui Cui,Fei Yang,Dongping Wei,Haomin Li,Jianfeng Shu,Yanli Bi,Xiaoqing Dai,Longyuan Gong,Yi Sun,Yongchao Zhao
Oncogene. 2019;
[Pubmed]  [Google Scholar] [DOI]
28 Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer
Wei Fu,Zhiming Hong,Xujun You,Jing Din,Baishu Chen,Beibei Zhao,Gengyan Yuan,Qixin Li
Biomedicine & Pharmacotherapy. 2019; 118: 109374
[Pubmed]  [Google Scholar] [DOI]
29 Long non-coding RNA CRNDE promote the progression of tongue squamous cell carcinoma through regulating the PI3K/AKT/mTOR signaling pathway
Zhongheng Yang,Weizhi Chen
RSC Advances. 2019; 9(37): 21381
[Pubmed]  [Google Scholar] [DOI]
30 Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
Toshihiko Doi,Yutaka Fujiwara,Nobuaki Matsubara,Junichi Tomomatsu,Satoru Iwasa,Akari Tanaka,Chihiro Endo-Tsukude,Shintaro Nakagawa,Shunji Takahashi
Cancer Chemotherapy and Pharmacology. 2019; 84(2): 393
[Pubmed]  [Google Scholar] [DOI]
31 Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
Sirin Saranyutanon,Sanjeev Kumar Srivastava,Sachin Pai,Seema Singh,Ajay Pratap Singh
Cancers. 2019; 12(1): 51
[Pubmed]  [Google Scholar] [DOI]
32 PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence
Arunaksharan Narayanankutty
Current Drug Targets. 2019; 20(12): 1217
[Pubmed]  [Google Scholar] [DOI]
33 The Secret Life of Translation Initiation in Prostate Cancer
Greco Hernández,Jorge L. Ramírez,Abraham Pedroza-Torres,Luis A. Herrera,Miguel A. Jiménez-Ríos
Frontiers in Genetics. 2019; 10
[Pubmed]  [Google Scholar] [DOI]
34 An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells
Zhizhuo Zhang,Kern Rei Chng,Shreyas Lingadahalli,Zikai Chen,Mei Hui Liu,Huy Hoang Do,Shaojiang Cai,Nicola Rinaldi,Huay Mei Poh,Guoliang Li,Ying Ying Sung,Charlie L. Heng,Leighton J. Core,Si Kee Tan,Xiaoan Ruan,John T. Lis,Manolis Kellis,Yijun Ruan,Wing-Kin Sung,Edwin Cheung
Genome Research. 2019; 29(2): 223
[Pubmed]  [Google Scholar] [DOI]
35 Dairy Products: Is There an Impact on Promotion of Prostate Cancer? A Review of the Literature
Alexandra Vasconcelos,Teresa Santos,Paula Ravasco,Pedro Miguel Neves
Frontiers in Nutrition. 2019; 6
[Pubmed]  [Google Scholar] [DOI]
36 miR-122 and miR-199 synergistically promote autophagy in?oral lichen planus by targeting the Akt/mTOR pathway
Liang Wang,Wei Wu,Jijun Chen,Youhua Li,Ming Xu,Yawei Cai
International Journal of Molecular Medicine. 2019;
[Pubmed]  [Google Scholar] [DOI]
37 Gene Expression Studies to Identify Significant Genes in AR, MTOR, MAPK Pathways and their Overlapping Regulatory Role in Prostate Cancer
Nimisha Asati,Abhinav Mishra,Ankita Shukla,Tiratha Raj Singh
Journal of Integrative Bioinformatics. 2019; 0(0)
[Pubmed]  [Google Scholar] [DOI]
38 MYSM1-AR complex-mediated repression of Akt/c-Raf/GSK-3ß signaling impedes castration-resistant prostate cancer growth
Jinbo Sun,Xiangnan Hu,Yongheng Gao,Qisheng Tang,Zhining Zhao,Wenjin Xi,Fan Yang,Wei Zhang,Yue Song,Bin Song,Tao Wang,He Wang
Aging. 2019; 11(22): 10644
[Pubmed]  [Google Scholar] [DOI]
39 Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgen-independent growth of prostate cancer cells
Huarong Huang,Yan He,Lanyue Zhang,Hongping Xiang,Dongli Li,Wenfeng Liu,Xue-Tao Xu,Susan Goodin,Kun Zhang,Xi Zheng
Food & Function. 2018;
[Pubmed]  [Google Scholar] [DOI]
40 Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
Brandon Bumbaca,Wei Li
Acta Pharmaceutica Sinica B. 2018;
[Pubmed]  [Google Scholar] [DOI]
41 T-cell lymphomas associated gene expression signature: Bioinformatics analysis based on gene expression Omnibus
Lei-lei Zhou,Xiao-yue Xu,Jie Ni,Xia Zhao,Jian-wei Zhou,Ji-feng Feng
European Journal of Haematology. 2018;
[Pubmed]  [Google Scholar] [DOI]
42 NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer
Zhixiong Chen,Qilong Jiang,Pingyu Zhu,Yanlin Chen,Xuemei Xie,Zhongbo Du,Li Jiang,Wei Tang
The Prostate. 2018;
[Pubmed]  [Google Scholar] [DOI]
43 Targeting AR-Beclin 1 Complex-Modulated Growth Factor Signaling Increases the Antiandrogen-Enzalutamide Sensitivity to Better Suppress the Castration-Resistant Prostate Cancer Growth
Meng Zhang,Yin Sun,Jialin Meng,Li Zhang,Chaozhao Liang,Chawnshang Chang
Cancer Letters. 2018;
[Pubmed]  [Google Scholar] [DOI]
44 miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA
Shengping Zhang,Jiarong Cai,Wenjun Xie,Hui Luo,Fei Yang
Experimental and Therapeutic Medicine. 2018;
[Pubmed]  [Google Scholar] [DOI]
45 MiR-93 functions as a tumor promoter in prostate cancer by targeting disabled homolog 2 (DAB2) and an antitumor polysaccharide from green tea (Camellia sinensis) on their expression
Ke Yang,Yuan-Wei Li,Zhi-Yong Gao,Wei Xiao,Tie-Qiu Li,Wei Song,Jue Zheng,Hao Chen,Gui-Heng Chen,Hao-Yu Zou
International Journal of Biological Macromolecules. 2018;
[Pubmed]  [Google Scholar] [DOI]
46 Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer
H. Alexander Ebhardt,Alex Root,Yansheng Liu,Nicholas Paul Gauthier,Chris Sander,Ruedi Aebersold
npj Systems Biology and Applications. 2018; 4(1)
[Pubmed]  [Google Scholar] [DOI]
47 Influence and mechanism of Angiotensin 1-7 on biological properties of normal prostate epithelial cells
Kamila Dominska,Piotr Okla,Karolina Kowalska,Dominika Ewa Habrowska-Górczynska,Kinga Anna Urbanek,Tomasz Ochedalski,Agnieszka Wanda Piastowska-Ciesielska
Biochemical and Biophysical Research Communications. 2018; 502(1): 152
[Pubmed]  [Google Scholar] [DOI]
48 Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats
Bianca Facchim Gonçalves,Silvana Gisele Pegorin de Campos,Wagner José Fávaro,Joyce Zalotti Brandt,Cristiane Figueiredo Pinho,Luis Antônio Justulin,Sebastião Roberto Taboga,Wellerson Rodrigo Scarano
Hormones and Cancer. 2018;
[Pubmed]  [Google Scholar] [DOI]
49 A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers
Philipp Y Maximov,Balkees Abderrahman,Ramona F Curpan,Yousef M Hawsawi,Ping Fan,V Craig Jordan
Endocrine-Related Cancer. 2018; 25(2): R83
[Pubmed]  [Google Scholar] [DOI]
50 A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer
Nisha R. Dahiya,Balaji Chandrasekaran,Venkatesh Kolluru,Murali Ankem,Chendil Damodaran,Manicka V. Vadhanam
Molecular Carcinogenesis. 2018;
[Pubmed]  [Google Scholar] [DOI]
51 Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
Zhonglin Cai,Weijie Chen,Jianzhong Zhang,Hongjun Li
International Urology and Nephrology. 2018;
[Pubmed]  [Google Scholar] [DOI]
52 Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas
Tomotaka Shimura,Yuichiro Tada,Hideaki Hirai,Daisuke Kawakita,Satoshi Kano,Kiyoaki Tsukahara,Akira Shimizu,Soichiro Takase,Yorihisa Imanishi,Hiroyuki Ozawa,Kenji Okami,Yuichiro Sato,Yukiko Sato,Chihiro Fushimi,Hideaki Takahashi,Takuro Okada,Hiroki Sato,Kuninori Otsuka,Yoshihiro Watanabe,Akihiro Sakai,Koji Ebisumoto,Takafumi Togashi,Yushi Ueki,Hisayuki Ota,Mizuo Ando,Shinji Kohsaka,Toyoyuki Hanazawa,Hideaki Chazono,Yoshiyuki Kadokura,Hitome Kobayashi,Toshitaka Nagao
Oncotarget. 2018; 9(2): 1852
[Pubmed]  [Google Scholar] [DOI]
53 Interaction between 3-Bromopyruvate and SC-514 in prostate cancer treatment
Toluleke Oloruntobi Famuyiwa,Joubin Jebelli,James Kwasi Kumi Diaka,Waseem Asghar
Journal of Cancer Prevention & Current Research. 2018; 9(6)
[Pubmed]  [Google Scholar] [DOI]
54 PI3K pathway in prostate cancer: All resistant roads lead to PI3K
Soonbum Park,Young Sik Kim,Davis Yeon Kim,Insuk So,Ju-Hong Jeon
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2018; 1870(2): 198
[Pubmed]  [Google Scholar] [DOI]
55 A Systems-Level Analysis of Mechanisms of Platycodon grandiflorum Based on A Network Pharmacological Approach
Musun Park,Sa-Yoon Park,Hae-Jeung Lee,Chang-Eop Kim
Molecules. 2018; 23(11): 2841
[Pubmed]  [Google Scholar] [DOI]
56 Clinical implications of PTEN loss in prostate cancer
Tamara Jamaspishvili,David M. Berman,Ashley E. Ross,Howard I. Scher,Angelo M. De Marzo,Jeremy A. Squire,Tamara L. Lotan
Nature Reviews Urology. 2018;
[Pubmed]  [Google Scholar] [DOI]
57 Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes
Matthew Utter,Sohag Chakraborty,Limor Goren,Lucas Feuser,Yuan-Shan Zhu,David A. Foster
Cancer Letters. 2018;
[Pubmed]  [Google Scholar] [DOI]
58 A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
Laura Graham,Kalyan Banda,Alba Torres,Brett S. Carver,Yu Chen,Katie Pisano,Greg Shelkey,Tracy Curley,Howard I. Scher,Tamara L. Lotan,Andrew C. Hsieh,Dana E. Rathkopf
Investigational New Drugs. 2018;
[Pubmed]  [Google Scholar] [DOI]
59 A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
Xiao X. Wei,Andrew C. Hsieh,Won Kim,Terence Friedlander,Amy M. Lin,Mirela Louttit,Charles J. Ryan
The Oncologist. 2017; 22(5): 503
[Pubmed]  [Google Scholar] [DOI]
60 Mechanisms of Therapeutic Resistance in Prostate Cancer
Mary Nakazawa,Channing Paller,Natasha Kyprianou
Current Oncology Reports. 2017; 19(2)
[Pubmed]  [Google Scholar] [DOI]
61 IL-8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF-?B pathway in prostate cancer
Yidi Guo,Ying Zang,Lianzheng Lv,Feng Cai,Tingting Qian,Guoying Zhang,Quancheng Feng
Molecular Medicine Reports. 2017; 16(6): 9035
[Pubmed]  [Google Scholar] [DOI]
62 Synergistic effects of phenylhexyl isothiocyanate and LY294002 on the PI3K/Akt signaling pathway in HL-60 cells
Huicong Yang,Yiqun Huang,Yong Zou,Xudong Ma
Oncology Letters. 2017; 14(3): 3043
[Pubmed]  [Google Scholar] [DOI]
63 SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway
Benjiang Qian,Yi Yao,Changming Liu,Jiabing Zhang,Huihong Chen,Huizhang Li
International Journal of Oncology. 2017; 50(5): 1601
[Pubmed]  [Google Scholar] [DOI]
64 mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia
Fabio Di Domenico,Antonella Tramutola,Cesira Foppoli,Elizabeth Head,Marzia Perluigi,D. Allan Butterfield
Free Radical Biology and Medicine. 2017;
[Pubmed]  [Google Scholar] [DOI]
65 Investigational serine/threonine kinase inhibitors against prostate cancer metastases
Claudio Festuccia
Expert Opinion on Investigational Drugs. 2017; 26(1): 25
[Pubmed]  [Google Scholar] [DOI]
66 Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways
Ewelina Górowska-Wójtowicz,Anna Hejmej,Alicja Kaminska,Laura Pardyak,Malgorzata Kotula-Balak,Joanna Dulinska-Litewka,Piotr Laidler,Barbara Bilinska
Toxicology in Vitro. 2017;
[Pubmed]  [Google Scholar] [DOI]
67 miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A
Xiaodi Qiu,Ying Dou
Biomedicine & Pharmacotherapy. 2017; 88: 430
[Pubmed]  [Google Scholar] [DOI]
68 Acne vulgaris: the metabolic syndrome of the pilo-sebaceous follicle
Bodo C. Melnik
Clinics in Dermatology. 2017;
[Pubmed]  [Google Scholar] [DOI]
69 Clinicopathological signature of p21-activated kinase 1 in prostate cancer and its regulation of proliferation and autophagy via the mTOR signaling pathway
Zhanyu Wang,Guojin Jia,Yan Li,Jikai Liu,Jinfang Luo,Jihong Zhang,Guoxiong Xu,Gang Chen
Oncotarget. 2017; 8(14): 22563
[Pubmed]  [Google Scholar] [DOI]
70 Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways
Guanzhao Liang,Musang Liu,Qiong Wang,Yongnian Shen,Huan Mei,Dongmei Li,Weida Liu
Oncotarget. 2017; 8(17): 28510
[Pubmed]  [Google Scholar] [DOI]
71 MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer
Song Xu,Jingping Ge,Zhengyu Zhang,Wenquan Zhou
Biomedicine & Pharmacotherapy. 2017; 96: 634
[Pubmed]  [Google Scholar] [DOI]
72 Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
Giovanni Luca Gravina,Andrea Mancini,Alessandro Colapietro,Francesco Marampon,Roberta Sferra,Simona Pompili,Leda Assunta Biordi,Roberto Iorio,Vincenzo Flati,Christian Argueta,Yosef Landesman,Michael Kauffman,Sharon Shacham,Claudio Festuccia
Oncotarget. 2017; 8(67): 111225
[Pubmed]  [Google Scholar] [DOI]
73 PTEN loss and activation of K-RAS and ß-catenin cooperate to accelerate prostate tumourigenesis
Matthew T Jefferies,Adam C Cox,Boris Y Shorning,Valerie Meniel,David Griffiths,Howard G Kynaston,Matthew J Smalley,Alan R Clarke
The Journal of Pathology. 2017; 243(4): 442
[Pubmed]  [Google Scholar] [DOI]
74 The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer
L S DæAbronzo,S Bose,M E Crapuchettes,R E Beggs,R L Vinall,C G Tepper,S Siddiqui,M Mudryj,F U Melgoza,B P Durbin-Johnson,R W deVere White,P M Ghosh
Oncogene. 2017;
[Pubmed]  [Google Scholar] [DOI]
75 Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer
Cuicui Zhu,Qingyi Zhu,Zhaomeng Wu,Yingying Yin,Dan Kang,Shan Lu,Ping Liu
Journal of Cellular Physiology. 2017;
[Pubmed]  [Google Scholar] [DOI]
76 Protein kinase B
Bhumika Wadhwa,Ubaid Makhdoomi,Ram Vishwakarma,Fayaz Malik
Anti-Cancer Drugs. 2017; 28(6): 569
[Pubmed]  [Google Scholar] [DOI]
77 MiR-1271 Inhibits Cell Growth in Prostate Cancer by Targeting ERG
Miao Wang,Wei Gao,Dehong Lu,Lianghong Teng
Pathology & Oncology Research. 2017;
[Pubmed]  [Google Scholar] [DOI]
78 AR Signaling and the PI3K Pathway in Prostate Cancer
Megan Crumbaker,Leila Khoja,Anthony Joshua
Cancers. 2017; 9(4): 34
[Pubmed]  [Google Scholar] [DOI]
79 The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells
C Morell,A Bort,D Vara,A Ramos-Torres,N Rodríguez-Henche,I Díaz-Laviada
Prostate Cancer and Prostatic Diseases. 2016;
[Pubmed]  [Google Scholar] [DOI]
80 Effects of Brassicaceae Isothiocyanates on Prostate Cancer
Silvia Novío,María Cartea,Pilar Soengas,Manuel Freire-Garabal,María Núñez-Iglesias
Molecules. 2016; 21(5): 626
[Pubmed]  [Google Scholar] [DOI]
81 mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma
Suzan Stelloo,Joyce Sanders,Ekaterina Nevedomskaya,Jeroen de Jong,Dennis Peters,Geert J.L.H. van Leenders,Guido Jenster,Andries M. Bergman,Wilbert Zwart
Oncotarget. 2016; 7(22): 32916
[Pubmed]  [Google Scholar] [DOI]
82 MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity
Yang Wang,Ning Shao,Xueying Mao,Minmin Zhu,Weifei Fan,Zhixiang Shen,Rong Xiao,Chuncai Wang,Wenping Bao,Xinyu Xu,Chun Yang,Jian Dong,Deshui Yu,Yan Wu,Caixia Zhu,Liting Wen,Xiaojie Lu,Yong-Jie Lu,Ninghan Feng
Oncotarget. 2016; 7(30): 47444
[Pubmed]  [Google Scholar] [DOI]
83 Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy
Xuechao Wan,Honglei Pu,Wenhua Huang,Shu Yang,Yalong Zhang,Zhe Kong,Zhuoran Yang,Peiqing Zhao,Ao Li,Tao Li,Yao Li
Oncotarget. 2016; 7(32): 51284
[Pubmed]  [Google Scholar] [DOI]
84 The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models
Yun-Rong Zhu,Xiao-zhong Zhou,Lun-qing Zhu,Chen Yao,Jian-Feng Fang,Feng Zhou,Xiong-Wei Deng,Yun-Qing Zhang
Oncotarget. 2016; 7(31): 49527
[Pubmed]  [Google Scholar] [DOI]
85 Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy
Fan Xu,Yujing Gao,Yanqing Wang,Jiahua Pan,Jianjun Sha,Xiaoguang Shao,Xunlei Kang,Jun Qin,M. James You,Yiran Huang,Baijun Dong,Wei Xue
Oncotarget. 2016; 7(39): 63294
[Pubmed]  [Google Scholar] [DOI]
86 Nimbolide, a neem limonoid inhibits Phosphatidyl Inositol-3 Kinase to activate Glycogen Synthase Kinase-3ß in a hamster model of oral oncogenesis
Josephraj Sophia,Kranthi Kiran Kishore T.,Jaganathan Kowshik,Rajakishore Mishra,Siddavaram Nagini
Scientific Reports. 2016; 6: 22192
[Pubmed]  [Google Scholar] [DOI]
87 Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro
Jasmina Makarevic,Igor Tsaur,Eva Juengel,Hendrik Borgmann,Karen Nelson,Christian Thomas,Georg Bartsch,Axel Haferkamp,Roman A. Blaheta
Life Sciences. 2016; 147: 137
[Pubmed]  [Google Scholar] [DOI]
88 Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Pier-Luc Clermont,Francesco Crea,Yan Ting Chiang,Dong Lin,Amy Zhang,James Z. L. Wang,Abhijit Parolia,Rebecca Wu,Hui Xue,Yuwei Wang,Jiarui Ding,Kelsie L. Thu,Wan L. Lam,Sohrab P. Shah,Colin C. Collins,Yuzhuo Wang,Cheryl D. Helgason
Clinical Epigenetics. 2016; 8(1)
[Pubmed]  [Google Scholar] [DOI]
89 Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients
S. Sideris,F. Aoun,C. N. Martinez,S. Latifyan,A. Awada,G. Costante,T. Gil
Journal of Endocrinological Investigation. 2016;
[Pubmed]  [Google Scholar] [DOI]
90 Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer
M. Pistelli,Z. Ballatore,A. Santinelli,T. Biscotti,F. Piva,G. Occhipinti,A. Della Mora,A. Pagliacci,N. Battelli,L. Bastianelli,M. De lisa,R. Bracci,E. Maccaroni,R. Berardi,S. Cascinu
Oncology Reports. 2016; 36(2): 755
[Pubmed]  [Google Scholar] [DOI]
91 Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LC-MS/MS
Sandeep R. Kunati,Yan Xu
Biomedical Chromatography. 2016;
[Pubmed]  [Google Scholar] [DOI]
92 Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression
Xuechao Wan,Wenhua Huang,Shu Yang,Yalong Zhang,Pu Zhang,Zhe Kong,Tao Li,Hai Wu,Fengxiang Jing,Yao Li
The International Journal of Biochemistry & Cell Biology. 2016; 79: 249
[Pubmed]  [Google Scholar] [DOI]
93 Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors
Yang Liu,Yanzhen Yin,Jingya Zhang,Krystle Nomie,Liang Zhang,Dezhi Yang,Michael L. Wang,Guisen Zhao
Archiv der Pharmazie. 2016; : n/a
[Pubmed]  [Google Scholar] [DOI]
94 mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Cara M. Statz,Sara E. Patterson,Susan M. Mockus
Targeted Oncology. 2016;
[Pubmed]  [Google Scholar] [DOI]
95 Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
Patricia Mucci LoRusso
Journal of Clinical Oncology. 2016; 34(31): 3803
[Pubmed]  [Google Scholar] [DOI]
96 Novel Cancer Chemotherapy Hits by Molecular Topology: Dual Akt and Beta-Catenin Inhibitors
Riccardo Zanni,Maria Galvez-Llompart,Cecilia Morell,Nieves Rodríguez-Henche,Inés Díaz-Laviada,Maria Carmen Recio-Iglesias,Ramon Garcia-Domenech,Jorge Galvez,Yuan-Soon Ho
PLOS ONE. 2015; 10(4): e0124244
[Pubmed]  [Google Scholar] [DOI]
97 HOXA1 enhances the cell proliferation, invasion and metastasis of prostate cancer cells
Haitao Wang,Guanzhong Liu,Dan Shen,Huamao Ye,Jinming Huang,Li Jiao,Yinghao Sun
Oncology Reports. 2015;
[Pubmed]  [Google Scholar] [DOI]
98 Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo
Shang-jun Jiang,Shuo Wang
Tumor Biology. 2015; 36(10): 8177
[Pubmed]  [Google Scholar] [DOI]
99 Milk—A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation
Bodo Melnik
International Journal of Molecular Sciences. 2015; 16(8): 17048
[Pubmed]  [Google Scholar] [DOI]
100 Derivatives containing both coumarin and benzimidazole potently induce caspase-dependent apoptosis of cancer cells through inhibition of PI3K-AKT-mTOR signaling
Haitao Liu,Yubin Wang,Ashok Sharma,Rui Mao,Na Jiang,Boying Dun,Jin-Xiong She
Anti-Cancer Drugs. 2015; : 1
[Pubmed]  [Google Scholar] [DOI]
101 Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors
A. C. Hsieh,H. G. Nguyen,L. Wen,M. P. Edlind,P. R. Carroll,W. Kim,D. Ruggero
Science Signaling. 2015; 8(403): ra116
[Pubmed]  [Google Scholar] [DOI]
102 The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence
David Schörghofer,Katharina Kinslechner,Andrea Preitschopf,Birgit Schütz,Clemens Röhrl,Markus Hengstschläger,Herbert Stangl,Mario Mikula
Reproductive Biology and Endocrinology. 2015; 13(1)
[Pubmed]  [Google Scholar] [DOI]
103 An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
Jianqing Lin,Aileen Deng,Jean Hoffman-Censits,Geoffrey Gibney,Terry Hyslop,Brooke Miller,Deborah Kilpatrick,Serge Jabbour,William Kevin Kelly
Cancer Treatment Communications. 2015; 4: 192
[Pubmed]  [Google Scholar] [DOI]
104 Persistent androgen receptor addiction in castration-resistant prostate cancer
Michael T. Schweizer,Evan Y. Yu
Journal of Hematology & Oncology. 2015; 8(1)
[Pubmed]  [Google Scholar] [DOI]
105 Transcription factor and microRNA-regulated network motifs for cancer and signal transduction networks
Wen-Tsong Hsieh,Ke-Rung Tzeng,Jin-Shuei Ciou,Jeffrey JP Tsai,Nilubon Kurubanjerdjit,Chien-Hung Huang,Ka-Lok Ng
BMC Systems Biology. 2015; 9(Suppl 1): S5
[Pubmed]  [Google Scholar] [DOI]
106 ACSL4 promotes prostate cancer growth, invasion and hormonal resistance
Xinyu Wu,Fangming Deng,Yirong Li,Garrett Daniels,Xinxin Du,Qinghu Ren,Jinhua Wang,Ling Hang Wang,Yang Yang,Valerio Zhang,David Zhang,Fei Ye,Jonathan Melamed,Marie E. Monaco,Peng Lee
Oncotarget. 2015; 6(42): 44849
[Pubmed]  [Google Scholar] [DOI]
107 PI3K/Akt signaling in osteosarcoma
Jian Zhang,Xiao-Hua Yu,Yi-Guo Yan,Cheng Wang,Wen-Jun Wang
Clinica Chimica Acta. 2015; 444: 182
[Pubmed]  [Google Scholar] [DOI]
108 VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
Zheren Shao,Qi Bao,Fangzhen Jiang,Huan Qian,Quan Fang,Xueqing Hu,Cong Cao
PLOS ONE. 2015; 10(7): e0132655
[Pubmed]  [Google Scholar] [DOI]
109 Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism
Jing-Wen Shih,Ling-Yu Wang,Chiu-Lien Hung,Hsing-Jien Kung,Chia-Ling Hsieh
International Journal of Molecular Sciences. 2015; 16(12): 28943
[Pubmed]  [Google Scholar] [DOI]
110 PIP5K1  inhibition as a therapeutic strategy for prostate cancer
J. M. Drake,J. Huang
Proceedings of the National Academy of Sciences. 2014; 111(35): 12578
[Pubmed]  [Google Scholar] [DOI]

 

Read this article